CiRA, Dainippon Sumitomo Pharma and Hitachi prepare for clinical trial on iPS-cell-derived dopamine neural progenitor cells

Jointly with Prof. Atsushi TAKAHASHI of CiRA, DSP and Hitachi have initiated experiments on the mass-production of dopamine neural progenitor cells derived from iPS cells and are preparing for doctor-initiated clinical trial on treatment for Parkinson’s disease in 2018.

Dainippon Sumitomo Pharma news release, July 24, 2015; Nikkei Biotech news release, February 6, 2017

CiRA, Dainippon Sumitomo Pharma and Hitachi prepare for clinical trial on iPS-cell-derived dopamine neural progenitor cells
Scroll to top